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Summary
This phase 1 study sought to characterize the safety, tolerability, and pharmacokinetic behavior of VLX1570, a small molecule
inhibitor of the deubiquitinases (DUBs) that remove sterically bulky ubiquitin chains from proteins during processing in the19S
regulatory subunit of the proteasome, in patients with relapsed and refractory multiple myeloma (MM). Fourteen patients were
treated with escalating doses of VLX1570 ranging from 0.05 to 1.2 mg/kg as a brief intravenous (IV) infusion on Days 1, 2, 8, 9,
15, and 16 of a 28-day cycle. Due to its poor aqueous solubility, VLX1570 was formulated in polyethylene glycol,
polyoxyethylated castor oil, and polysorbate 80 and administered as a brief intravenous (IV) infusion via a central venous
catheter. Anti-myeloma effects were noted at doses at or above 0.6 mg/kg, however, two patients treated at the 1.2 mg/kg dose
level experienced severe, abrupt, and progressive respiratory insufficiency, which was associated with diffuse pulmonary infil-
trates on imaging studies, similar to those rarely noted with bortezomib and other inhibitors of the 20S proteasome, culminating in
death. Although the contribution of VLX1570’s formulation to the pulmonary toxicity could not be ruled out, the severity and
precipitous nature of the toxicity and the steep relationship between dose and toxicity, the study was discontinued. Despite the
severe pulmonary toxicity noted with VLX1570, efforts directed at identifying DUB inhibitors with greater therapeutic indices
appear warranted based on the unique mechanism of action, robustness of preclinical antitumor activity, and activity of the DUB
inhibitors in MM resistant to PIs targeting the 20S proteasome subunit.
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Introduction
Targeting proteasome function is a principal therapeutic
pillar in the treatment of multiple myeloma (MM) and oth-
er plasma cell dyscrasias [1–3]. In the current era of
clinical medicine, most patients diagnosed with MM are
typically treated with at least one proteasome inhibitor
(PI), but drug resistance invariably develops [2, 3].
Currently available proteasome inhibitors, including the
prototypical PI bortezomib and next generation PIs,
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carfilzomib, ixazomib, and others, target the 20S protea-
some subunit, in which proteins encounter the proteolytic
active site of the proteasome and undergo degradation
[1–3]. The central core of the 20S subunit is narrow and
gated by the N-terminal tails of the α ring subunits, thereby
requiring protein substrates to be at least partially unfolded
before entering the core [1, 3] The dynamic process of
protein unfolding before entering the core is facilitated by
deubiquitinases (DUBs), which remove sterically bulky
ubiquitin chains in the 19S regulatory subunit of the pro-
teasome [4–11]. The small molecule VLX1570 (Fig. 1) and
an analog b-AP15 specifically block the activity of DUBs
USP14 and UCHL5 in the 19S regulatory subunit, which
results in the rapid accumulation of high molecular weight
ubiquitin conjugates, proteasome shutdown, and robust
anti-tumor activity in well-established orthotopic and xe-
nograft models of MM, lymphoma, Ewing’s sarcoma, and
other malignancies [4–11]. In addition to demonstrating
robust cytotoxic activity and cellular responses like
bortezomib in preclinical models of MM, VLX1570 pos-
sessed prominent activity in bortezomib-resistant MM
[9–11]. In rats, the maximum tolerated dose (MTD) of
VLX1570, which required formulation in polyethylene
glycol, polyoxyethylated castor oil, and polysorbate 80 in
due to its poor aqueous solubility, was 3.3 mg/kg
(20 mg/kg) as a 10-min intravenous (IV) infusion on two
consecutive days weekly for 4 weeks.12 The highest dose
investigated, 6.6 mg/kg caused transient dyspnea, minimal
to slight hyperplasia of the alveolar epithelium, and mor-
tality in 3 of 15 rats [12]. There were no findings indicative
of respiratory distress as a cause of mortality at that time.
In cynomolgus monkeys, the no adverse effect level
(NOAEL) was the highest feasible dose of 2.2 mg/kg, with
higher doses (3.3 and 6 mg/kg subcutaneously and IV)
associated with severe injection site reactions due to the
formulation. Other notable effects included transient cyto-
penia and mild hemolysis attributed to polysorbate 80. In
both species, VLX1570 was rapidly distributed and cleared
from plasma with mean elimination half-life values rang-
ing from 5 to 8 min, which was predicted by the extensive
and rapid drug metabolism observed in ex vivo hepatocyte
and animal studies. The unique mechanism of action, ac-
tivity in bortezomib-resistant MM, and tolerability of
VLX1570 provided the rationale to initiate clinical devel-
opment in relapsed and refractory MM.
Here, we report our experience with single-agent
VLX1570 administered IV over 10–30 min on Days 1, 2, 8,
9, 15, and 16 of a 28-day cycle in a multicenter phase 1 study
(NCT02372240). The primary objective was to determine the
MTD of VLX1570 on this administration schedule and rec-
ommend a dose for subsequent phase 2 studies in patients with
relapsed and refractory MM and other relevant malignancies.
Secondary objectives were to characterize the adverse events
and safety profile of VLX1570, its pharmacokinetic (PK) be-
havior, and evaluate preliminary evidence of anti-cancer
activity.
Patients and methods
This study, which was performed at five institutions in the
United States of America and Finland, was comprised of
two stages. Stage 1 was a dose-escalation stage, in which the
safety and tolerability of VLX1570 was assessed to recom-
mend a dose for subsequent Phase 2 studies disease directed
studies, whereas Stage 2 was planned as a Phase 2 study, in
which as many as 26 patients were to receive treatment at the
recommended phase 2 dose established in Stage 1. Toxicity
was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version
4.0. Response was assessed by International Myeloma
Working Group criteria after each cycle [13].
Principal eligibility criteria included patients withMMwho
had been refractory to or relapsed after treatment with at least
one immunomodulatory drug (IMiD) and one PI. Patients
were required to have: an Eastern Cooperative Oncology
Group performance status of 0–2, age ≥ 18 years; measurable
disease, as defined by at least one of the following: serum
monoclonal protein ≥0.5 g/dL; urine monoclonal protein
>200 mg/24 h; and/or serum immunoglobulin free light chain
>10 mg/dL and an abnormal kappa/lambda ratio (reference
range, 0.26–1.65). All patients had to have adequate bone
marrow reserves (defined as absolute neutrophil count
≥1000/mm3, platelets ≥75,000/mm3, hemoglobin ≥8 g/dL),
hepatic function (bilirubin ≤1.5 times the upper limit of nor-
mal [ULN], alanine aminotransferase and aspartate amino-
transferase values ≤2.5 times the ULN) and renal function
(estimated glomerular filtration rate ≥ 30mL/min). Female pa-
tients must have been of non-childbearing potential or have
had a negative serum pregnancy test and bothmale and female
patients must have been willing to use effective contraception
throughout the study and for 6 months following last study
treatment. All patients must have been willing to provide in-
formed written consent according to institutional guidelines.Fig. 1 Chemical Structure of VLX1570
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VX1570 was formulated in polyethylene glycol,
polyoxyethylated castor oil, and polysorbate 8. 0Based on
observations in the rat toxicity study and the inability to de-
termine an MTD in monkeys due to VLX570’s formulation,
the agent was administered by a central venous catheter and
respiratory and cardiovascular functions were monitored in
the peri-treatment period. The premedication regimen, largely
instituted based on the nature of the formulation consisted of:
dexamethasone 20 mg orally/IV, diphenhydramine 50 mg
oral/IV or an equivalent H1-histamine antagonist, and an H2-
antagonist (cimetidine 300 mg oral/IV, ranitidine 50 mg
oral/IV, or famotidine 20 mg IV).
In accordance with Food and Drug Administration guid-
ance, the starting dose was determined to be 0.05 mg/kg,
which was equivalent to one-tenth of the MTD in the most
sensitive species (3.3 mg/kg in rats that corresponded to a
human equivalent dose of 0.2 mg/kg after adjusting for
body surface area). However, much higher starting doses
could also be derived using acceptable alternative method-
ologies, including one-sixth of the highest non-severely
toxic dose in nonrodent species (weight adjusted human
equivalent, 0.37 mg/kg) or the human equivalent of an
animal weight-adjusted NOAEL in the most sensitive spe-
cies (0.22 mg/kg). Because of the high probability that the
starting dose grossly underestimated therapeutically rele-
vant doses, the study utilized hyper-accelerated dose titra-
tion in the first patient cohort, in which there was intra-
patient dose escalation twice in the first treatment cycle,
followed by accelerated dose titration in patient cohorts 2
and 3, in which there was intra-patient dose escalation be-
tween cycles 1 and 2 (Table 1). The dose-limiting toxicity
(DLT) evaluation period was two cycles (8 weeks). An
assessment of drug exposure between the 0.6 and 1.2 mg/kg
dose levels was planned to confirm the appropriateness of
dose escalation based on weight.
Blood sampling for pharmacokinetic (PK) studies was per-
formed pretreatment, immediately after the end of treatment
and at 0.25, 0.5, 1, 1.5. and 3 h post-treatment on days 1 and
15. Sampling was performed pretreatment, immediately after
the end of treatment on day 2. VLX1570 was assayed in plas-
ma using a validated liquid chromatography tandem mass
spectrometry method with a lower limit of quantification of
1.0 ng/mLThe plasma concentration data were analyzed using
the program PK-Solutions 2.0TM (Summit Research Services
and Software, Montrose CO). Non-compartmental pharmaco-
kinetic analysis was applied.
The study and all amendments were approved by the insti-
tutional review boards at participating sites, and patients gave
written informed consent.
Results
Fifteen patients were enrolled into the study, of whom 14
patients, whose relevant disease characteristics are shown in
Table 2, received drug treatment. Four and eight patients, were
treated with VLX1570 in cohort 1 (dose levels, 0.05, 0.10 and
0.15 mg/kg) and cohort 2 (dose levels, 0.30 and 0.60 mg/kg),
respectively, with three patients in each cohort being evaluable
for toxicity and the remaining patients withdrawn from study
due to progressive disease. In cohort 2, three of four patients
received additional VLX1570 treatment at the 0.60 mg/kg
dose level. One cohort 2 patient who received four
VLX1570 cycles (one cycle at 0.30 mg/kg and three cycles
at 0.60 mg/kg) after developing rapid progression of an IgA
kappa MM on standard therapy prior to study entry experi-
enced improved overall functionality and constitutional symp-
toms, as well as modest decrements of several MMparameters
compared to pretreatment baseline, including serumMprotein
(0.80 to 0.60 mg/dL), 24-h urine M protein excretion (184 to
Table 1 Dose escalation scheme













1a (Hyper-accelerated Titration) 4 1 0.05 4 4 0
2 0.15 4 4 0
3 0.30 4 8 0
2b (Accelerated Titration) 8 3 0.30 8 8 0
4 0.60 3 8 0










a Fifteen patients were enrolled and 14 patients were treated. One patient was withdrawn per protocol due to
significant neutropenia prior to VLX1570 treatment
b Hyper-accelerated titration cohorts with intra-patient dose escalation
c Accelerated titration with intra-patient dose escalation
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81 mg); urine kappa free light chain (FLC) (114 to 91 mg/L),
and kappa/lambda FLC ratio (51 to 18), consistent with stable
disease. Adverse events (AEs), possibly related to VLX1570,
but likely confounded by disease, included grade 1–2 fatigue,
rash, nausea, and anemia; DLT was not observed.
In contrast to the relative lack of AEs in cohorts 1 and 2,
fatal pulmonary toxicity occurred in the first two cohort 3
patients within days of receiving two doses of VLX1570
1.2 mg/kg. The first patient, a 58-year-old female who had
received extensive prior anti-MM therapy, including four pro-
teasome inhibitors and an autologous stem cell transplantation
(ASCT), had experienced a severe pulmonary event, charac-
terized by bilateral pulmonary infiltrates that were attributed
to an atypical pneumonia 10 months prior to study. On
VLX1570 treatment day 3, she developed cough, fever, dys-
pnea, and hypoxia, and diffuse bilateral ground glass opacities
on computerized tomography (CT), all of which worsened
over the next week. She also developed severe anemia requir-
ing transfusions and thrombocytopenia (platelet count nadir,
17,000/mm3 on day 10) without clinical or laboratory evi-
dence of bleeding, hemolysis, or platelet consumption.
Despite receiving broad spectrum antibiotics and antifungals
and high-dose corticosteroids, the patient developed multi-
organ failure and expired on treatment day 10. A distinct in-
fectious etiology was not identified, but the event was initially
attributed to an atypical infection, largely in consideration of
her previous pulmonary event. The second patient, a 75-year-
old man who had also previously received extensive anti-MM
therapy, including bortezomib and carfilzomib, daratumumab,
and an ASCT, developed mild transient dyspnea during his
second VLX1570 treatment; a chest radiograph was unre-
markable. On day 3, however, he developed progressively
worsening dyspnea, hypoxia, and cough. Bilateral lung
infiltrates were noted on CT and both mechanical ventilation
and broad-spectrum antibiotics were begun. On day 5, high-
dose corticosteroids were administered post- bronchoscopy,
which did not reveal any specific findings nor positive cul-
tures; a lung biopsy was not performed. Like the previous
patient, transfusion-dependent anemia and thrombocytopenia
(platelet nadir, 9000/mm3 on day 10) without clinical or lab-
oratory evidence of bleeding, hemolysis, microangiopathy or
platelet consumption, were noted. The patient’s free serum
kappa light chain M-protein decreased from a pretreatment
value of 52.0 to 11.8 mg/dL on day 9 despite worsening renal
dysfunction, and most unfortunately, he expired on treatment
day 10 with multi-organ failure. After these severe pulmonary
AEs culminating in death, the study was terminated.
PK studies revealed that VLX1570 was not quantifiable at
doses less than 0.3 mg/kg nor at durations longer than 3 h
post-treatment at higher doses. Peak plasma concentrations
(Cmax) were measured in 11 patients at the end of 31 infusions
in the dosing range of 0.3–1.2 mg/kg; Cmax values ranged
from 2.0 to 68.5 ng/mL. Cmax values did not relate to body
weight. Assuming a plasma volume of 3000 mL, the magni-
tude of the Cmax values indicate that the amount present in the
plasma compartment at end of infusion was approximately
0.03–0.9% of the administered dose. These estimates are sim-
ilar to those resulting from studies in rats and monkeys and are
at least partly explained by the rapid metabolism of VLX1570
following infusion into the blood. Similarly, plasma clearance
rates ranged from 8 to 62, 11 to 32, and 42 to 94 L/h/kg,
respectively, at the 0.3, 0.6, and 1.2 mg/kg dose. These values
are much larger than estimates for liver blood flow and glo-
merular filtration rate, 1.5 and 0.12 L/h/kg, respectively, again
indicating that VLX1570 is rapidly metabolized following
infusion. The elimination half-life ranged between 0.17 and
1.01 h.
Interindividual variability was high and clearance was rap-
id, with half-life values averaging 0.49 ± 0.24 h. The rapid
clearance rate was much higher than the glomerular filtration
rate and liver blood flow, supporting preclinical results indi-
cating that VLX1570 is rapidly metabolized. The high
intraindividual variability, level of assay quantification, and
rapid clearance precluded accurate assessments of dose pro-
portionality and weight-based dosing. Although VLX1570
concentrations and exposure in both patients with severe pul-
monary toxicity were among the highest, several other patents
treated at lower doses without lung toxicity had higher values.
Discussion
Pulmonary toxicity, albeit rare, has also been reported with PIs
targeting the 20S proteasome subunit [14–16]. In a recent
literature review of 35 reports of pulmonary toxicity attributed
to bortezomib, most events were noted to occur after the first
Table 2 Patient Characteristics (n = 14)
n (%)
Median age (range), y 65 (46–78)
Female 7 (50%)
Median prior lines of therapy (range) 5 (2–14)
Prior PI 14 (100%)
At least two prior PIs 13 (93%)
Prior IMiD 14 (100%)
Prior pomalidomide 12 (86%)
Double refractory (PI and IMiD) 14 (100%)
Prior daratumumab 6 (43%)
Prior high-dose melphalan with ASCT 11 (79%)
Fifteen patients were enrolled and 14 patients were treated. One patient
was withdrawn due to neutropenia prior to VLX1570 treatment, as de-
tailed previously
ASCT autologous stem cell transplantation, IMiD immunomodulatory
imide drug, PI proteasome inhibitor
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several treatments and the mean duration from the last dose to
the onset of pulmonary symptoms was 3 days; pulmonary
toxicity was fatal in 37% of patients in the series [14].
Mortality did not relate to gender, prior lung disease, history
of smoking, concurrent or prior treatment with corticosteroids,
nor management with high-dose corticosteroids. Nonetheless,
rapid clinical improvement has been reported following treat-
ment with high-dose corticosteroids [15]. Although the under-
lying mechanism for PI-induced pulmonary toxicity is un-
clear, the withdrawal of the agents, possibly triggering re-
bound activation of (NF)-κB and lung inflammation, has been
proposed [14]. The preferential accumulation of active drug
metabolites in the lung, thereby resulting in direct damage to
tissues, is an alternative hypothesis [14]. The severe lung tox-
icity of VXL1570 at doses at which potential antitumor effects
were just beginning to be noted understates the robust, albeit
nonselective, inhibitory effects of targeting the upstream 19S
regulatory proteasome subunit with VLX1570. The contribu-
tion of the components in VLX1570’s formulation to the pul-
monary events must also be considered, however, the excipi-
ents are not known to confer such effects.
To better understand these clinical observations, a rat mod-
el of VLX1570-induced lung toxicity has recently been devel-
oped. Rats treated with VLX1570 and a related analog devel-
oped dose-related respiratory dysfunction, as well as multifo-
cal hyperplasia of the alveolar and, to a lesser degree, of the
bronchiolar epithelium, associated with an intra-alveolar ac-
cumulation of macrophages. The effects appear to be en-
hanced by the PCT formulation. Further, bortezomib formu-
lation in PCT was also associated with similar findings; thus,
this model is being used to elucidate the mechanism of
VLX1570-induced lung toxicity and identify DUB inhibitors
with greater selective for cancer than lung tissue. Despite the
severe pulmonary toxicity noted with VLX1570 in the present
study, efforts directed at identifying DUB inhibitors with
greater therapeutic indices appear warranted based on the
unique mechanism of action, robustness of preclinical antitu-
mor activity, and activity of the DUB inhibitors in MM resis-
tant to PIs targeting the 20S proteasome subunit.
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